Adrenal Incidentaloma: What Happens After an Accidental CT Finding, When Imaging Is Enough, and When Surgery Is Needed

Research-informed explainer — last updated April 12, 2026

An adrenal mass found unexpectedly on CT scanning — called an incidentaloma — is discovered in up to 5% of adults who undergo abdominal imaging, and the great majority are benign, non-functioning adenomas that require no surgery. The key to avoiding unnecessary operations while not missing the few dangerous lesions is a structured two-part evaluation: hormonal testing to look for autonomous secretion, and imaging characterization to assess malignancy risk.

This article is informed by William Young, MD, Tyson Family Endocrinology Clinical Professor and Chair of Endocrinology at Mayo Clinic in Rochester, who authored the foundational NEJM clinical problem-solving article on the incidentally discovered adrenal mass (1,092 citations) and led the Endocrine Society guideline on primary aldosteronism management (2,813 citations); Beverly Biller, MD, Professor of Medicine at Harvard Medical School and Massachusetts General Hospital, who led the Endocrine Society guideline on diagnosing Cushing's syndrome (2,630 citations) — the first hormonal test ordered for every incidentaloma; Jeffrey Mechanick, MD, Professor of Medicine at Mount Sinai Hospital in New York, co-author of the AACE and AAES medical guidelines for management of adrenal incidentalomas (494 citations); Tobias Else, MD, at the University of Michigan, who authored the comprehensive adrenocortical carcinoma review in Endocrine Reviews (877 citations) and European guidelines on adrenocortical carcinoma (912 citations); and Mouhammed Habra, MD, at MD Anderson Cancer Center, whose work covers malignancy risk stratification and ACC management (88 citations).

How common are adrenal incidentalomas?

With widespread CT scanning for unrelated conditions — abdominal pain, kidney stones, cancer staging — the adrenal glands are now frequently imaged as bystanders. Autopsy studies and imaging series estimate that 4–7% of adults have adrenal masses, with prevalence increasing with age. The vast majority — more than 80% — are benign non-functioning adenomas. However, a subset are hormonally active, and a small fraction are malignant. Sorting these out requires a systematic approach, not watchful waiting.

The first question: is the mass making hormones?

All patients with an adrenal incidentaloma should undergo three hormonal assessments:

1. Subclinical Cushing's syndrome (autonomous cortisol secretion) The standard test is a 1-mg overnight dexamethasone suppression test. A cortisol level above 1.8 mcg/dL suggests incomplete suppression and warrants further evaluation. The Cushing's diagnosis guideline (2,630 citations) recommends confirmatory testing with late-night salivary cortisol or 24-hour urinary free cortisol. Even without classic Cushingoid features, autonomous cortisol secretion raises risks of hypertension, diabetes, fracture, and cardiovascular disease.

2. Pheochromocytoma Plasma free metanephrines or 24-hour urinary fractionated metanephrines must be measured before any surgical or invasive procedure, since an unsuspected pheochromocytoma manipulated without alpha-blockade can cause a lethal hypertensive crisis. This test is mandatory even if the patient has no symptoms.

3. Primary aldosteronism (in hypertensive patients) The Endocrine Society guideline recommends measuring an aldosterone-to-renin ratio in all hypertensive patients with an adrenal mass. Primary aldosteronism — overproduction of aldosterone — is far more common than previously believed, affecting 5–10% of unselected hypertensives and much higher proportions of those with resistant hypertension.

The second question: does the CT appearance suggest malignancy?

Imaging characteristics on non-contrast CT are highly informative:

• Hounsfield units (HU) below 10: strongly suggests lipid-rich adenoma (benign); more than 70% of adenomas qualify
• HU 10–20: indeterminate; delayed contrast washout CT or MRI chemical shift imaging can help
• HU above 20: more suspicious; needs further characterization
• Size above 4 cm: risk of adrenocortical carcinoma increases substantially

The AACE/AAES guidelines (494 citations) use size and imaging attenuation together to guide surgical versus surveillance decisions. A mass with lipid-rich features (HU < 10) and no hormonal activity can generally be followed with imaging rather than operated on.

Adrenocortical carcinoma: rare but serious

Adrenocortical carcinoma (ACC) accounts for fewer than 2% of adrenal incidentalomas but carries a poor prognosis when advanced. Dr. Else's Endocrine Reviews comprehensive review (877 citations) describes a bimodal incidence peak in children and in adults aged 40–50. Key red flags on imaging include: size above 6 cm, irregular borders, heterogeneity, invasion of adjacent structures, and rapid growth on interval imaging. When ACC is suspected, referral to a high-volume center is essential — outcomes are significantly better when the initial operation achieves complete resection.

Dr. Habra's work at MD Anderson demonstrates that overt hypercortisolism in resected ACC patients predicts worse outcomes, reinforcing why hormonal characterization matters even when imaging appears non-concerning.

When is surgery the right answer?

Surgery is recommended when:

• The mass is hormonally active (pheochromocytoma, primary aldosteronism with unilateral adrenal source, overt cortisol excess)
• The mass has imaging features concerning for malignancy (large, heterogeneous, HU > 20, rapid growth)
• Size is greater than 4 cm with indeterminate imaging features

Surgery is generally not recommended for:

• Small (< 4 cm), lipid-rich, non-functioning adenomas
• Bilateral small adenomas consistent with bilateral hyperplasia
• Patients who are not surgical candidates

Surveillance for those not having surgery

If surgery is deferred, the AACE/AAES guidelines recommend:

• Repeat hormonal testing at 1 year to detect new autonomous secretion
• Repeat imaging at 6–12 months, then annually for 1–2 years if stable
• Surgery reconsidered if size increases by more than 1 cm or new hormonal activity emerges

Questions to ask your doctor

• Which hormonal tests should I have, and does the order in which I take any medications affect the results?
• What are the specific HU and size measurements from my CT, and what do they mean for my risk?
• If my tests suggest subclinical cortisol excess, what health consequences does that carry?
• Does my mass have any features on imaging that make adrenocortical carcinoma a concern?
• If I need surgery, is laparoscopic adrenalectomy feasible for my case, and what is the expected recovery?
• If we are watching this over time, what change in size or blood tests would prompt re-evaluation?

The bottom line

An adrenal incidentaloma is a common finding that rarely requires surgery — but all masses must be evaluated with structured hormonal testing and careful imaging interpretation before a management plan is set. Pheochromocytoma, primary aldosteronism, and autonomous cortisol secretion each have specific treatments that improve outcomes; missing them carries real risks. When malignancy is suspected, prompt referral to a specialist center makes a decisive difference.